Bioxytran, Inc. (BIXT)
USD 0.13
(-15.4%)
USD 0.13
(-15.4%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.82 Million USD | 78.7% |
| 2022 | 2.13 Million USD | -49.28% |
| 2021 | 4.21 Million USD | 232.18% |
| 2020 | 1.26 Million USD | -22.24% |
| 2019 | 1.63 Million USD | 659.85% |
| 2018 | 214.71 Thousand USD | -46.01% |
| 2017 | 397.68 Thousand USD | -51.59% |
| 2016 | 821.47 Thousand USD | -62.87% |
| 2015 | 2.21 Million USD | 59.13% |
| 2014 | 1.39 Million USD | -36.58% |
| 2013 | 2.19 Million USD | -11.62% |
| 2012 | 2.48 Million USD | 2.88% |
| 2011 | 2.41 Million USD | 606.84% |
| 2010 | 341.13 Thousand USD | 25.35% |
| 2009 | 272.14 Thousand USD | 1023.89% |
| 2008 | 24.21 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 783.79 Thousand USD | -23.66% |
| 2024 Q3 | 347.72 Thousand USD | -43.19% |
| 2024 Q2 | 609.38 Thousand USD | -22.25% |
| 2023 Q2 | 1.02 Million USD | 36.38% |
| 2023 Q3 | 987.26 Thousand USD | -3.57% |
| 2023 Q4 | 1.02 Million USD | 4.0% |
| 2023 FY | 3.82 Million USD | 78.7% |
| 2023 Q1 | 750.75 Thousand USD | -5.32% |
| 2022 Q2 | 537.22 Thousand USD | -41.05% |
| 2022 Q1 | 911.35 Thousand USD | -2.63% |
| 2022 FY | 2.13 Million USD | -49.28% |
| 2022 Q4 | 792.91 Thousand USD | 6055.53% |
| 2022 Q3 | -13.31 Thousand USD | -102.48% |
| 2021 Q1 | 1.68 Million USD | 117.56% |
| 2021 Q3 | 547.24 Thousand USD | -47.5% |
| 2021 FY | 4.21 Million USD | 232.18% |
| 2021 Q4 | 935.96 Thousand USD | 71.03% |
| 2021 Q2 | 1.04 Million USD | -38.28% |
| 2020 Q3 | 114.44 Thousand USD | 2.27% |
| 2020 FY | 1.26 Million USD | -22.24% |
| 2020 Q2 | 111.9 Thousand USD | -57.94% |
| 2020 Q1 | 266.04 Thousand USD | -46.76% |
| 2020 Q4 | 776.3 Thousand USD | 578.3% |
| 2019 FY | 1.63 Million USD | 659.85% |
| 2019 Q4 | 499.66 Thousand USD | -41.24% |
| 2019 Q2 | 106.49 Thousand USD | -17.84% |
| 2019 Q1 | 129.62 Thousand USD | -22.03% |
| 2019 Q3 | 850.31 Thousand USD | 698.44% |
| 2018 Q2 | 124.86 Thousand USD | 385.29% |
| 2018 Q4 | 166.24 Thousand USD | 249.8% |
| 2018 FY | 214.71 Thousand USD | -46.01% |
| 2018 Q1 | 25.73 Thousand USD | 1865.62% |
| 2018 Q3 | 47.52 Thousand USD | -61.94% |
| 2017 Q3 | 29.25 Thousand USD | -89.5% |
| 2017 FY | 397.68 Thousand USD | -51.59% |
| 2017 Q1 | 56.39 Thousand USD | 155.57% |
| 2017 Q4 | 1309.00 USD | -95.53% |
| 2017 Q2 | 278.54 Thousand USD | 393.88% |
| 2016 FY | 821.47 Thousand USD | -62.87% |
| 2016 Q4 | -101.49 Thousand USD | -136.91% |
| 2016 Q1 | 467.81 Thousand USD | 332.74% |
| 2016 Q3 | 274.98 Thousand USD | 52.62% |
| 2016 Q2 | 180.17 Thousand USD | -61.48% |
| 2015 FY | 2.21 Million USD | 59.13% |
| 2015 Q1 | 85.15 Thousand USD | -13.49% |
| 2015 Q2 | 1.95 Million USD | 2200.31% |
| 2015 Q3 | 71.14 Thousand USD | -96.37% |
| 2015 Q4 | 108.1 Thousand USD | 51.96% |
| 2014 Q2 | 82 Thousand USD | -7.24% |
| 2014 Q3 | 1.12 Million USD | 1267.65% |
| 2014 FY | 1.39 Million USD | -36.58% |
| 2014 Q4 | 98.43 Thousand USD | -91.22% |
| 2014 Q1 | 88.4 Thousand USD | -45.45% |
| 2013 Q4 | 162.06 Thousand USD | -44.03% |
| 2013 FY | 2.19 Million USD | -11.62% |
| 2013 Q1 | 1.06 Million USD | 52.62% |
| 2013 Q2 | 686.88 Thousand USD | -35.61% |
| 2013 Q3 | 289.55 Thousand USD | -57.85% |
| 2012 Q1 | 131.11 Thousand USD | -89.78% |
| 2012 Q2 | 275.5 Thousand USD | 110.13% |
| 2012 Q4 | 698.92 Thousand USD | 51.63% |
| 2012 Q3 | 460.93 Thousand USD | 67.3% |
| 2012 FY | 2.48 Million USD | 2.88% |
| 2011 Q4 | 1.28 Million USD | 443.36% |
| 2011 FY | 2.41 Million USD | 606.84% |
| 2011 Q2 | 162.83 Thousand USD | -77.66% |
| 2011 Q1 | 728.73 Thousand USD | 971.9% |
| 2011 Q3 | 236.2 Thousand USD | 45.06% |
| 2010 Q4 | 67.98 Thousand USD | -4.4% |
| 2010 FY | 341.13 Thousand USD | 25.35% |
| 2010 Q2 | 125.37 Thousand USD | 64.3% |
| 2010 Q1 | 76.3 Thousand USD | -44.82% |
| 2010 Q3 | 71.11 Thousand USD | -43.28% |
| 2009 Q4 | 138.27 Thousand USD | 62.41% |
| 2009 Q3 | 85.14 Thousand USD | 134.04% |
| 2009 Q1 | 12.87 Thousand USD | 0.0% |
| 2009 Q2 | 36.37 Thousand USD | 182.6% |
| 2009 FY | 272.14 Thousand USD | 1023.89% |
| 2008 FY | 24.21 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -186.061% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 24.234% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 87.074% |
| Nascent Biotech, Inc. | 2.22 Million USD | -71.316% |
| Rebus Holdings, Inc. | 664 Thousand USD | -475.323% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 89.746% |
| Qrons Inc. | 643.67 Thousand USD | -493.488% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -880.616% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 93.349% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -819.456% |
| Skye Bioscience, Inc. | 13.54 Million USD | 71.802% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 95.598% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 22.322% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1359.598% |
| SQZ Biotechnologies Company | 85.61 Million USD | 95.538% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -30.996% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -154.354% |
| Mesoblast Limited | 5.9 Million USD | 35.274% |
| Marizyme, Inc. | 19.23 Million USD | 80.145% |
| Genus plc | 147.7 Million USD | 97.414% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 56.487% |
| Pharming Group N.V. | 225.49 Million USD | 98.306% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -86.466% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -184.757% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 54.189% |
| ContraFect Corporation | 56.88 Million USD | 93.285% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 13.349% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -158.336% |
| IMV Inc. | 37.7 Million USD | 89.869% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -36.905% |
| MultiCell Technologies, Inc. | 567.42 USD | -673148.564% |
| ONE Bio Corp. | 6.44 Million USD | 40.717% |
| Accustem Sciences Inc. | 3.74 Million USD | -1.968% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 95.555% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -618.124% |
| Q BioMed Inc. | 3.43 Million USD | -11.16% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 84.543% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -45.39% |
| Biomind Labs Inc. | 994.18 Thousand USD | -284.25% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 96.154% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -117.094% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 43.136% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -104.903% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 15380.588% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 76.139% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -108.172% |
| GB Sciences, Inc. | 1.42 Million USD | -168.928% |
| Alpha Cognition Inc. | 9.7 Million USD | 60.64% |
| HST Global, Inc. | 140.9 Thousand USD | -2611.112% |
| CSL Limited | 3.44 Billion USD | 99.889% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -239.596% |
| Halberd Corporation | 74.84 Thousand USD | -5004.282% |
| Enzolytics Inc. | 2.17 Million USD | -75.276% |
| Agentix Corp. | 1.37 Million USD | -178.486% |
| Resverlogix Corp. | 12.71 Million USD | 69.948% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -4.641% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.751% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -265.914% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -58.846% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -141.88% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -12.193% |
| AVAX Technologies, Inc. | 7.31 Million USD | 47.743% |
| Zenith Capital Corp. | 8.94 Million USD | 57.283% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.537% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -21828.403% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -55.587% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -2127.374% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -98.872% |
| Kadimastem Ltd | 2.41 Million USD | -58.505% |
| Helix BioMedix, Inc. | 1.97 Million USD | -93.716% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 64.846% |
| BioStem Technologies, Inc. | 22.97 Million USD | 83.372% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -2004.938% |
| LadRx Corporation | 3.81 Million USD | -0.219% |
| Cell Source, Inc. | 4.32 Million USD | 11.68% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -313.655% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -313.655% |
| NovAccess Global Inc. | 2.46 Million USD | -54.865% |
| Affymax, Inc. | 39.38 Million USD | 90.301% |
| Itoco Inc. | 919.14 Thousand USD | -315.621% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 9.868% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -241.389% |
| Mobile Lads Corp. | 554.54 Thousand USD | -588.878% |
| CytoDyn Inc. | 18.05 Million USD | 78.845% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -15077.985% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1635.815% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -169.064% |
| SYBLEU INC | 160.87 Thousand USD | -2274.591% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -110.323% |
| International Stem Cell Corporation | 5.27 Million USD | 27.525% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -7156.842% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -18678.681% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 89.466% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -136.103% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -419.158% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -22.795% |
| Neutra Corp. | 243.82 Thousand USD | -1466.783% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 78.117% |
| PureTech Health plc | 144.59 Million USD | 97.358% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 81.356% |
| IXICO plc | 4.7 Million USD | 18.841% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 56.574% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 96.756% |
| CSL Limited | 3.89 Billion USD | 99.902% |
| Cellectis S.A. | 97.32 Million USD | 96.075% |